Avanos Medical Financial Statements (AVNS)
|
|
|
|
Report date
|
|
|
06.05.2025 |
05.08.2025 |
05.11.2025 |
24.02.2026 |
05.05.2026 |
|
05.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
167.5 |
175.0 |
177.8 |
180.9 |
182.2 |
|
715.9 |
|
Operating Income, bln rub |
|
|
7.30 |
7.30 |
13.1 |
-89.3 |
12.2 |
|
-56.7 |
|
EBITDA, bln rub |
? |
|
21.4 |
-63.9 |
10.00 |
13.0 |
22.4 |
|
-18.5 |
|
Net profit, bln rub |
? |
|
6.60 |
-76.8 |
-1.40 |
3.70 |
5.10 |
|
-69.4 |
|
|
OCF, bln rub |
? |
|
25.7 |
6.80 |
14.0 |
28.2 |
-12.3 |
|
36.7 |
|
CAPEX, bln rub |
? |
|
6.70 |
11.0 |
7.00 |
6.90 |
4.30 |
|
29.2 |
|
FCF, bln rub |
? |
|
19.0 |
-4.20 |
7.00 |
21.3 |
-16.6 |
|
7.50 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
82.5 |
84.8 |
68.0 |
175.3 |
76.2 |
|
404.3 |
|
Cost of production, bln rub |
|
|
77.7 |
82.9 |
96.7 |
94.9 |
93.8 |
|
368.3 |
|
R&D, bln rub |
|
|
5.40 |
5.80 |
5.80 |
6.10 |
5.20 |
|
22.9 |
|
Interest expenses, bln rub |
|
|
2.10 |
2.00 |
1.80 |
1.90 |
1.50 |
|
7.20 |
|
|
Assets, bln rub |
|
|
1 108 |
1 039 |
1 068 |
1 074 |
1 050 |
|
1 050 |
|
Net Assets, bln rub |
? |
|
839.4 |
776.3 |
778.0 |
778.2 |
782.1 |
|
782.1 |
|
Debt, bln rub |
|
|
140.9 |
137.3 |
133.7 |
129.1 |
138.4 |
|
138.4 |
|
Cash, bln rub |
|
|
97.0 |
90.3 |
70.5 |
89.8 |
65.6 |
|
65.6 |
|
Net debt, bln rub |
|
|
43.9 |
47.0 |
63.2 |
39.3 |
72.8 |
|
72.8 |
|
|
Ordinary share price, rub |
|
|
14.3 |
12.2 |
11.6 |
11.2 |
14.0 |
|
21.5 |
|
Number of ordinary shares, mln |
|
|
46.1 |
46.1 |
46.4 |
46.4 |
46.4 |
|
46.4 |
|
|
Market cap, bln rub |
|
|
661 |
564 |
536 |
521 |
650 |
|
999 |
|
EV, bln rub |
? |
|
705 |
611 |
600 |
560 |
723 |
|
1 072 |
|
Book value, bln rub |
|
|
276 |
290 |
262 |
266 |
273 |
|
273 |
|
|
EPS, rub |
? |
|
0.14 |
-1.67 |
-0.03 |
0.08 |
0.11 |
|
-1.50 |
|
FCF/share, rub |
|
|
0.41 |
-0.09 |
0.15 |
0.46 |
-0.36 |
|
0.16 |
|
BV/share, rub |
|
|
5.99 |
6.28 |
5.64 |
5.72 |
5.89 |
|
5.89 |
|
|
EBITDA margin, % |
? |
|
12.8% |
-36.5% |
5.62% |
7.19% |
12.3% |
|
-2.58% |
|
Net margin, % |
? |
|
3.94% |
-43.9% |
-0.79% |
2.05% |
2.80% |
|
-9.69% |
|
FCF yield, % |
? |
|
17.3% |
15.6% |
14.0% |
8.27% |
1.15% |
|
0.75% |
|
ROE, % |
? |
|
-45.8% |
-59.7% |
-60.3% |
-8.73% |
-8.87% |
|
-8.87% |
|
ROA, % |
? |
|
-34.7% |
-44.6% |
-43.9% |
-6.32% |
-6.61% |
|
-6.61% |
|
|
P/E |
? |
|
-1.72 |
-1.22 |
-1.14 |
-7.67 |
-9.37 |
|
-14.4 |
|
P/FCF |
|
|
5.79 |
6.42 |
7.16 |
12.1 |
86.7 |
|
133.3 |
|
P/S |
? |
|
0.96 |
0.81 |
0.77 |
0.74 |
0.91 |
|
1.40 |
|
P/BV |
? |
|
2.39 |
1.95 |
2.05 |
1.96 |
2.38 |
|
3.66 |
|
EV/EBITDA |
? |
|
-2.07 |
-1.44 |
-1.37 |
-28.7 |
-39.1 |
|
-58.0 |
|
Debt/EBITDA |
|
|
-0.13 |
-0.11 |
-0.14 |
-2.02 |
-3.94 |
|
-3.94 |
|
|
R&D/CAPEX, % |
|
|
80.6% |
52.7% |
82.9% |
88.4% |
120.9% |
|
78.4% |
|
|
CAPEX/Revenue, % |
|
|
4.00% |
6.29% |
3.94% |
3.81% |
2.36% |
|
4.08% |
|
| Avanos Medical shareholders |
